4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study
J.C-H. Yang(National Taiwan University), Yoon Jun Kim(Seoul National University Bundang Hospital), SH Lee(Samsung Medical Center), B. Liu(Harbin Medical University), Y.V. Ostapenko(National Cancer Institute), Shun Lu(Shanghai Jiao Tong University), Adlinda Alip(University of Malaya), Ernesto Korbenfeld(Hospital Británico de Buenos Aires), Josiane Mourão Dias(Hospital de Câncer de Barretos), Pongwut Danchaivijitr(Siriraj Hospital), N. Girard(Université de Versailles Saint-Quentin-en-Yvelines), Enriqueta Felip(Universitat Autònoma de Barcelona), H. Hayashi(Kindai University), Alexander I. Spira(Virginia Cancer Specialists), Benjamin Besse(Université Paris-Saclay), Tingting Sun(Johnson & Johnson (United States)), Marguerite Ennis(Johnson & Johnson (United States)), Seema Sethi(Johnson & Johnson (United States)), Joshua Bauml(Johnson & Johnson (United States)), Byoung Chul Cho(Yonsei University)
Cited by 43Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis